Monday 22 September 2003
Tenascin-X may be a new diagnostic marker of malignant mesothelioma in the differential diagnosis of cancers involving the serosal cavities, particularly in the differential diagnosis between this tumor and ovarian/peritoneal serous carcinoma. (#19738457#)
haploinsufficiency of TNXB is associated with hypermobility type of Ehlers-Danlos syndrome (MIM.130020) and Ehlers-Danlos-like syndrome (MIM.606408) (#12865992#)
Tenascin XB (TNXB) has been identified as a gene that is more highly expressed in malignant mesothelioma compared with ovarian/peritoneal serous carcinoma based on gene expression array analysis.
Tenascin C and tenascin XB are possibly involved in tumorigenesis associated with neurofibromatosis type 1. (#17202312#)
Tenascin-X is a novel diagnostic marker of malignant mesothelioma. Yuan Y, Nymoen DA, Stavnes HT, Rosnes AK, Bjørang O, Wu C, Nesland JM, Davidson B. Am J Surg Pathol. 2009 Nov;33(11):1673-82. PMID: #19738457#
Microarray-based identification of tenascin C and tenascin XB, genes possibly involved in tumorigenesis associated with neurofibromatosis type 1. Lévy P, Ripoche H, Laurendeau I, Lazar V, Ortonne N, Parfait B, Leroy K, Wechsler J, Salmon I, Wolkenstein P, Dessen P, Vidaud M, Vidaud D, Bièche I. Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):398-407. PMID: #17202312#